RxDoctor Payments Data

Diana Hilbert, MD

Internal Medicine · San Francisco, CANPI 1386642551

Payments from drug & device makers

$5,546in general payments, 2019–2025

Across 265 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Merck$560
  • Pfizer$546
  • Gilead$454
  • Novo Nordisk$388
  • GSK$331
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,51199%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,546 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$214,711
Medicare patients
599
Services billed
2,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl15$101,786
EliquisApixaban66$62,846
JanuviaSitagliptin Phosphate63$60,221
JardianceEmpagliflozin46$39,180
XareltoRivaroxaban31$37,504
OzempicSemaglutide20$27,512
FarxigaDapagliflozin Propanediol19$22,018
TivicayDolutegravir Sodium11$9,823
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,712
CreonLipase/Protease/Amylase15$5,325
MyrbetriqMirabegron12$5,242
Atorvastatin Calcium478$4,765
Levothyroxine Sodium204$4,291
SynthroidLevothyroxine Sodium44$3,464
Wixela InhubFluticasone Propion/Salmeterol15$3,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$546$62,84666 claims
MerckJanuvia$560$60,22163 claims
Boehringer IngelheimJardiance, Stiolto Respimat$237$44,89258 claims
Johnson & JohnsonXarelto$120$37,50431 claims
Novo NordiskOzempic$388$27,51220 claims
AstraZenecaFarxiga$209$22,01819 claims
Viiv Healthcare CompanyTivicay$1,409$9,82311 claims
AbbVieCreon, Synthroid$300$8,78859 claims
Astellas Pharma US IncMyrbetriq$202$5,24212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →